{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:41:03Z","timestamp":1771666863543,"version":"3.50.1"},"publisher-location":"Dordrecht","reference-count":295,"publisher":"Springer Netherlands","isbn-type":[{"value":"9789400759701","type":"print"},{"value":"9789400759718","type":"electronic"}],"license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-94-007-5971-8_3","type":"book-chapter","created":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T17:52:06Z","timestamp":1363110726000},"page":"29-87","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Diabetes Mellitus: New Challenges and Innovative Therapies"],"prefix":"10.1007","author":[{"given":"Cristina M.","family":"Sena","sequence":"first","affiliation":[]},{"given":"Carla F.","family":"Bento","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Filipa","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Sei\u00e7a","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,1,28]]},"reference":[{"key":"3_CR1","unstructured":"World Health Organisation (2012) Diabetes fact sheet no 312"},{"key":"3_CR2","unstructured":"Centers for Disease Control and Prevention (2011) Diabetes data and trends. Available via; URL: http:\/\/apps.nccd.cdc.gov\/DDTSTRS\/default.aspx. Accessed 10 Jan 2013"},{"key":"3_CR3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2337\/diacare.28.3.617","volume":"28","author":"M Cusick","year":"2005","unstructured":"Cusick M, Meleth AD, Agr\u00f3n E, Fisher MR, Reed GF, Knatterud GL, Barton FB, Davis MD, Ferris FL 3rd, Chew EY, Early Treatment Diabetc Retinopathy Study Research Group (2005) Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes. Diabetes Care 28:617\u2013625","journal-title":"Diabetes Care"},{"key":"3_CR4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/pgmj.2008.075606","volume":"85","author":"V Mohan","year":"2009","unstructured":"Mohan V, Pradeepa R (2009) Mortality in diabetes mellitus: revisiting the data from a developing region of the world. Postgrad Med J 85:225\u2013226","journal-title":"Postgrad Med J"},{"key":"3_CR5","first-page":"978","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group (1993) The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-\u00addependent diabetes mellitus: the diabetes control and complications trial. N Engl J Med 329:978\u2013986","journal-title":"N Engl J Med"},{"key":"3_CR6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM199307293290502","volume":"329","author":"P Reichard","year":"1993","unstructured":"Reichard P, Nilsson B-Y, Rosenqvist U (1993) The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304\u2013309","journal-title":"N Engl J Med"},{"key":"3_CR7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"U.K. Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"U.K. Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352:837\u2013853","journal-title":"Lancet"},{"key":"3_CR8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"U.K. Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"U.K. Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854\u2013865","journal-title":"Lancet"},{"key":"3_CR9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","volume":"141","author":"E Selvin","year":"2004","unstructured":"Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421\u2013431","journal-title":"Ann Intern Med"},{"key":"3_CR10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1463-1326.2006.00698.x","volume":"9","author":"J Rosenstock","year":"2007","unstructured":"Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S (2007) Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 9:175\u2013185","journal-title":"Diabetes Obes Metab"},{"key":"3_CR11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2337\/dc06-1815","volume":"30","author":"J Rosenstock","year":"2007","unstructured":"Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A (2007) Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-\u00adblind, randomized trial. Diabetes Care 30:217\u2013223","journal-title":"Diabetes Care"},{"key":"3_CR12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-008-1157-y","volume":"52","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association; European Association for the Study of Diabetes (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17\u201330","journal-title":"Diabetologia"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc11-S011","volume":"34","author":"American Diabetes Association","year":"2011","unstructured":"American Diabetes Association (2011) Standard of medical care in diabetes. Diabetes Care 34:S11\u2013S61","journal-title":"Diabetes Care"},{"key":"3_CR14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2337\/diabetes.54.5.1253","volume":"54","author":"MA Atkinson","year":"2005","unstructured":"Atkinson MA (2005) Thirty years of investigating the autoimmune basis for type 1 diabetes. Diabetes 54:1253\u20131263","journal-title":"Diabetes"},{"key":"3_CR15","first-page":"90","volume":"106","author":"A Morales","year":"2009","unstructured":"Morales A (2009) A better future for children with type 1 diabetes: review of the conclusions from the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. J Ark Med Soc 106:90\u201393","journal-title":"J Ark Med Soc"},{"key":"3_CR16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jcb.22000","volume":"106","author":"ME Furth","year":"2009","unstructured":"Furth ME, Atala A (2009) Stem cell sources to treat diabetes. J Cell Biochem 106:507\u2013511","journal-title":"J Cell Biochem"},{"key":"3_CR17","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/08916930802200208","volume":"41","author":"CE Couri","year":"2008","unstructured":"Couri CE, Voltarelli JC (2008) Autologous stem cell transplantation for early type 1 diabetes mellitus. Autoimmunity 41:666\u2013672","journal-title":"Autoimmunity"},{"key":"3_CR18","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0140-6736(09)60609-7","volume":"373","author":"SA White","year":"2009","unstructured":"White SA, Shaw JA, Sutherland DE (2009) Pancreas transplantation. Lancet 373:1808\u20131817","journal-title":"Lancet"},{"key":"3_CR19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/j.ackd.2009.04.001","volume":"16","author":"AC Wiseman","year":"2009","unstructured":"Wiseman AC (2009) Simultaneous pancreas kidney transplantation: a critical appraisal of the risks and benefits compared with other treatment alternatives. Adv Chronic Kidney Dis 16:278\u2013287","journal-title":"Adv Chronic Kidney Dis"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MOT.0b013e328320a8ff","volume":"14","author":"G Tufveson","year":"2009","unstructured":"Tufveson G (2009) An experience of pancreas and islet transplantation in patients with end stage renal failure due to diabetes type I. Curr Opin Organ Transplant 14:95\u2013102","journal-title":"Curr Opin Organ Transplant"},{"key":"3_CR21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2337\/diab.37.4.413","volume":"37","author":"C Ricordi","year":"1988","unstructured":"Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW (1988) Automated method for isolation of human pancreatic islets. Diabetes 37:413\u2013420","journal-title":"Diabetes"},{"key":"3_CR22","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1371\/journal.pmed.0010058","volume":"1","author":"MA Naftanel","year":"2004","unstructured":"Naftanel MA, Harlan DM (2004) Pancreatic islet transplantation. PLoS Med 1:e58","journal-title":"PLoS Med"},{"key":"3_CR23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM200007273430401","volume":"343","author":"AM Shapiro","year":"2000","unstructured":"Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-\u00adfree immunosuppressive regimen. N Engl J Med 343:230\u2013238","journal-title":"N Engl J Med"},{"key":"3_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.tp.0000268511.64428.d8","volume":"84","author":"L Badet","year":"2007","unstructured":"Badet L, Benhamou PY, Wojtusciszyn A, Baertschiger R, Milliat-Guittard L, Kessler L, Penfornis A, Thivolet C, Renard E, Bosco D, Morel P, Morelon E, Bayle F, Colin C, Berney T, GRAGIL Group (2007) Expectations and strategies regarding islet transplantation: metabolic data from the GRAGIL 2 trial. Transplantation 84:89\u201396","journal-title":"Transplantation"},{"key":"3_CR25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1262-3636(06)72803-8","volume":"32","author":"T Berney","year":"2006","unstructured":"Berney T, Toso C (2006) Monitoring of the islet graft. Diabetes Metab 32:503\u2013512","journal-title":"Diabetes Metab"},{"key":"3_CR26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2337\/diabetes.47.4.559","volume":"47","author":"C Beger","year":"1998","unstructured":"Beger C, Cirulli V, Vajkoczy P, Halban PA, Menger MD (1998) Vascularization of purified pancreatic islet-like cell aggregates (pseudoislets) after syngerneic transplantation. Diabetes 47:559\u2013565","journal-title":"Diabetes"},{"key":"3_CR27","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.2337\/diabetes.51.5.1362","volume":"51","author":"G Mattsson","year":"2002","unstructured":"Mattsson G, Jansson L, Carlsson PO (2002) Decreased vascular density in mouse pancreatic islets after transplantation. Diabetes 51:1362\u20131366","journal-title":"Diabetes"},{"key":"3_CR28","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2337\/diabetes.54.7.2060","volume":"54","author":"EA Ryan","year":"2005","unstructured":"Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM (2005) Five-year follow up after clinical islet transplantation. Diabetes 54:2060\u20132069","journal-title":"Diabetes"},{"key":"3_CR29","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2337\/dc09-0490","volume":"32","author":"D Mineo","year":"2009","unstructured":"Mineo D, Pileggi A, Alejandro R, Ricordi C (2009) Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care 32:1563\u20131569","journal-title":"Diabetes Care"},{"key":"3_CR30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3748\/wjg.15.1153","volume":"15","author":"SS Mohseni Salehi Monfared","year":"2009","unstructured":"Mohseni Salehi Monfared SS, Larijani B, Abdollahi M (2009) Islets transplantation and antioxidant management: a comprehensive review. World J Gastroenterol 15:1153\u20131161","journal-title":"World J Gastroenterol"},{"key":"3_CR31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2337\/dc07-0975","volume":"31","author":"A Caumo","year":"2008","unstructured":"Caumo A, Maffi P, Nano R, Bertuzzi F, Luzi L, Secchi A, Bonifacio E, Piemonti L (2008) Transplant estimated function: a simple index to evaluate beta-cell secretion after islet transplantation. Diabetes Care 31:301\u2013305","journal-title":"Diabetes Care"},{"key":"3_CR32","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.3748\/wjg.v13.i20.2862","volume":"13","author":"Y Cheng","year":"2007","unstructured":"Cheng Y, Liu YF, Zhang JL, Li TM, Zhao N (2007) Elevation of vascular endothelial growth factor production and its effect on revascularization and function of graft islets in diabetic rats. World J Gastroenterol 13:2862\u20132866","journal-title":"World J Gastroenterol"},{"key":"3_CR33","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.transproceed.2008.11.015","volume":"41","author":"M Figliuzzi","year":"2009","unstructured":"Figliuzzi M, Cornolti R, Perico N, Rota C, Morigi M, Remuzzi G, Remuzzi A, Benigni A (2009) Bone marrow\u2013derived mesenchymal stem cells improve islet graft function in diabetic rats. Transplant Proc 41:1797\u20131800","journal-title":"Transplant Proc"},{"key":"3_CR34","unstructured":"Buss JL, Rajab A, Diakoff E, Wang J, Miller K, Osei K (2010) Exenatide pre-treatment improved islet graft function compared to treatment post-transplant only. Proc 70th scientific sessions meeting of the American diabetes association, Orlando, Abstract 141-OR"},{"key":"3_CR35","unstructured":"Vergani A, D\u2019Addio F, Petrelli A, Williams J, Sayegh MH, Fiorina P (2010) A combined strategy of thymoglobulin and CTLA4-iG cure diabetes and prevent recurrence of autoimmunity in NOD mice. Proc 70th scientific sessions meeting of the American diabetes association, Orlando, Abstract 336-OR"},{"key":"3_CR36","unstructured":"Delgado TC, Barosa C, Nunes PM, Jones JG (2010) Effects of cyclosporine A on glucose metabolism: implications for post-transplant diabetes mellitus. Proc 70th scientific sessions meeting of the American diabetes association, Orlando, Abstract 2042-P"},{"key":"3_CR37","unstructured":"Velazquez-Garcia SA, Rodriguez A, Salido E, Torres A (2010) Temporal administration of FK506 results in impaired glucose homeostasis and decreased beta cell proliferation in a rat model of insulin resistance. Proc 70th scientific sessions meeting of the American diabetes association, Orlando, Abstract 2052-P"},{"key":"3_CR38","unstructured":"Shivaswamy V, Griffin B, Clure C, Reyelts C, Calleroz A, Bennett RG, Hamel FG, Borgeson C, Larsen JL (2010) Metformin improves immunosuppressant-induced hyperglycaemia. Proc 70th scientific sessions meeting of the American diabetes association, Orlando, Abstract 2038-P"},{"key":"3_CR39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/01.tp.0000229418.60236.87","volume":"82","author":"R Olsson","year":"2006","unstructured":"Olsson R, Maxhuni A, Carlsson P (2006) Revascularization of transplanted pancreatic islets following culture with stimulators of angiogenesis. Transplantation 82:340\u2013347","journal-title":"Transplantation"},{"key":"3_CR40","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1007\/s00125-005-1922-0","volume":"48","author":"A King","year":"2005","unstructured":"King A, Lock J, Xu G, Bonner-Weir S, Weir GC (2005) Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 48:2074\u20132079","journal-title":"Diabetologia"},{"key":"3_CR41","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1111\/j.1600-6143.2006.01551.x","volume":"6","author":"JG Avila","year":"2006","unstructured":"Avila JG, Wang Y, Barbaro B, Gangemi A, Qi M, Kuechle J, Doubleday N, Doubleday M, Churchill T, Salehi P, Shapiro J, Philipson LH, Benedetti E, Lakey JR, Oberholzer J (2006) Improved outcomes in islet isolation and transplantation by the use of a novel hemoglobin-\u00adbased O2 carrier. Am J Transplant 6:2861\u20132870","journal-title":"Am J Transplant"},{"key":"3_CR42","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.2337\/diabetes.53.11.2804","volume":"53","author":"JL Contreras","year":"2004","unstructured":"Contreras JL, Eckstein C, Smyth CA, Bilbao G, Vilatoba M, Ringland SE, Young C, Thompson JA, Fern\u00e1ndez JA, Griffin JH, Eckhoff DE (2004) Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 53:2804\u20132814","journal-title":"Diabetes"},{"key":"3_CR43","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/db07-0358","volume":"56","author":"S Cabric","year":"2007","unstructured":"Cabric S, Sanchez J, Lundgren T, Foss A, Felldin M, K\u00e4llen R, Salmela K, Tibell A, Tufveson G, Larsson R, Korsgren O, Nilsson B (2007) Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 56:2008\u20132015","journal-title":"Diabetes"},{"key":"3_CR44","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2337\/db06-1653","volume":"56","author":"J Emamaullee","year":"2007","unstructured":"Emamaullee J, Stanton L, Schur C, Shapiro AM (2007) Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes 56:1289\u20131298","journal-title":"Diabetes"},{"key":"3_CR45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncpendmet0369","volume":"3","author":"P Witkowski","year":"2007","unstructured":"Witkowski P, Herold K (2007) Islet transplantation for type 1 diabetes\u2013where should we go? Nat Clin Pract Endocrinol Metab 3:2\u20133","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"3_CR46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nri2099","volume":"07","author":"YG Yang","year":"2007","unstructured":"Yang YG, Sykes M (2007) Xenotransplantation: current status and a perspective on the future. Nat Rev Immunol 07:519\u2013531","journal-title":"Nat Rev Immunol"},{"key":"3_CR47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1399-3089.2009.0545.x","volume":"16","author":"PJ O\u2019Connell","year":"2009","unstructured":"O\u2019Connell PJ (2009) The international xenotransplantation association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes\u2013chapter 6: patient selection for pilot clinical trials of islet xenotransplantation. Xenotransplantation 16:249\u2013254","journal-title":"Xenotransplantation"},{"key":"3_CR48","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s001090050337","volume":"77","author":"RP Lanza","year":"1999","unstructured":"Lanza RP, Ecker DM, K\u00fchtreiber WM, Marsh JP, Ringeling J, Chick WL (1999) Transplantation of islets using microencapsulation: studies in diabetic rodents and dogs. J Mol Med 77:206\u2013210","journal-title":"J Mol Med"},{"key":"3_CR49","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.transproceed.2006.03.014","volume":"38","author":"R Calafiore","year":"2006","unstructured":"Calafiore R, Basta G, Luca G, Lemmi A, Racanicchi L, Mancuso F, Montanucci MP, Brunetti P (2006) Standard technical procedures for microencapsulation of human islets for graft into nonimmunosuppressed patients with type 1 diabetes mellitus. Transplant Proc 38:1156\u20131157","journal-title":"Transplant Proc"},{"key":"3_CR50","unstructured":"Living Cell Technologies (2009) Open-label investigation of the safety and effectiveness of DIABECELL(R) in patients with type I diabetes mellitus. ClinicalTrials.gov identifier: NCT00940173. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00940173?term=porcine+islets&rank=1. Accessed 10 Jan 2013"},{"key":"3_CR51","unstructured":"Gao Y, Shao S, Xie B, Lim SK, Li G (2010) Transplantation of alginate-encapsulated insulin-\u00adproducing cells differentiated from embryonic stem\/progenitor cells. Proc 70th scientific sessions meeting of the American diabetes association, Orlando, (Abstract 2033-P)"},{"key":"3_CR52","unstructured":"Hathout E, Sakata N, Chan NK, Chrisler J, Obenaus A (2010) Co-transplantation with bone marrow improves islet function. Relation to nerve growth factor. 70th scientific sessions meeting of the American diabetes association, Orlando, (Abstract 2041-P)"},{"key":"3_CR53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.mce.2008.03.008","volume":"288","author":"M Best","year":"2008","unstructured":"Best M, Carroll M, Hanley NA, Piper Hanley K (2008) Embryonic stem cells to beta-cells by understanding pancreas development. Mol Cell Endocrinol 288:86\u201394","journal-title":"Mol Cell Endocrinol"},{"key":"3_CR54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2009.18","volume":"5","author":"R M\u00fcller","year":"2009","unstructured":"M\u00fcller R, Lengerke C (2009) Patient-specific pluripotent stem cells: promises and challenges. Nat Rev Endocrinol 5:195\u2013203","journal-title":"Nat Rev Endocrinol"},{"key":"3_CR55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nbt1393","volume":"26","author":"E Kroon","year":"2008","unstructured":"Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, Agulnick AD, D\u2019Amour KA, Carpenter MK, Baetge EE (2008) Pancreatic endoderm derived from human embryonic stem cells generates glucose-\u00adresponsive insulin-secreting cells in\u00a0vivo. Nat Biotechnol 26:443\u2013452","journal-title":"Nat Biotechnol"},{"key":"3_CR56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature05934","volume":"448","author":"K Okita","year":"2007","unstructured":"Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448:313\u2013317","journal-title":"Nature"},{"key":"3_CR57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nature06534","volume":"451","author":"IH Park","year":"2007","unstructured":"Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ (2007) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451:141\u2013146","journal-title":"Nature"},{"key":"3_CR58","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861\u2013872","journal-title":"Cell"},{"key":"3_CR59","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","volume":"318","author":"J Yu","year":"2007","unstructured":"Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917\u20131920","journal-title":"Science"},{"key":"3_CR60","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature05944","volume":"448","author":"M Wernig","year":"2007","unstructured":"Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R (2007) In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448:318\u2013324","journal-title":"Nature"},{"key":"3_CR61","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(05)67813-0","volume":"366","author":"CJ Taylor","year":"2005","unstructured":"Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA (2005) Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 366:2019\u20132025","journal-title":"Lancet"},{"key":"3_CR62","doi-asserted-by":"crossref","first-page":"31601","DOI":"10.1074\/jbc.M806597200","volume":"283","author":"K Tateishi","year":"2008","unstructured":"Tateishi K, He J, Taranova O, Liang G, D\u2019Alessio AC, Zhang Y (2008) Generation of insulin-\u00adsecreting islet-like clusters from human skin fibroblasts. J Biol Chem 283:31601\u201331607","journal-title":"J Biol Chem"},{"key":"3_CR63","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nature07863","volume":"458","author":"K Woltjen","year":"2009","unstructured":"Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, H\u00e4m\u00e4l\u00e4inen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung HK, Nagy A (2009) PiggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458:766\u2013777","journal-title":"Nature"},{"key":"3_CR64","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.297.14.1568","volume":"297","author":"JC Voltarelli","year":"2007","unstructured":"Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Sim\u00f5es BP, Foss MC, Squiers E, Burt RK (2007) Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297:1568\u20131576","journal-title":"JAMA"},{"key":"3_CR65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jsbmb.2007.03.023","volume":"104","author":"N Vicker","year":"2007","unstructured":"Vicker N, Su X, Ganeshapillai D (2007) Novel non-steroidal inhibitors of human 11 \u03b2-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol 104:123\u2013129","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3_CR66","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.exphem.2008.01.009","volume":"36","author":"MJ Haller","year":"2008","unstructured":"Haller MJ, Viener HL, Wasserfall C, Brusko T, Atkinson MA, Schatz DA (2008) Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol 36:710\u2013715","journal-title":"Exp Hematol"},{"key":"3_CR67","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/75050","volume":"6","author":"S Ferber","year":"2000","unstructured":"Ferber S, Halkin A, Cohen H, Ber I, Einav Y, Goldberg I, Barshack I, Seijffers R, Kopolovic J, Kaiser N, Karasik A (2000) Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin induced hyperglycaemia. Nat Med 6:568\u2013572","journal-title":"Nat Med"},{"key":"3_CR68","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s00125-005-1949-2","volume":"48","author":"JJ Meier","year":"2005","unstructured":"Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC (2005) Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48:2221\u20132228","journal-title":"Diabetologia"},{"key":"3_CR69","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaut.2007.02.010","volume":"28","author":"K Shternhall-Ron","year":"2007","unstructured":"Shternhall-Ron K, Quintana FJ, Perl S, Meivar-Levy I, Barshack I, Cohen IR, Ferber S (2007) Ectopic PDX-1 expression in liver ameliorates type 1 diabetes. J Autoimmun 28:134\u2013142","journal-title":"J Autoimmun"},{"key":"3_CR70","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1126\/science.290.5498.1959","volume":"290","author":"AT Cheung","year":"2000","unstructured":"Cheung AT, Dayanandan B, Lewis JT, Korbutt GS, Rajotte RV, Bryer-Ash M, Boylan MO, Wolfe MM, Kieffer TJ (2000) Glucose dependent insulin release from genetically engineered K cells. Science 290:1959\u20131962","journal-title":"Science"},{"key":"3_CR71","doi-asserted-by":"crossref","first-page":"31950","DOI":"10.1074\/jbc.M303127200","volume":"278","author":"I Ber","year":"2003","unstructured":"Ber I, Shternhall K, Perl S, Ohanuna Z, Goldberg I, Barshack I, Benvenisti-Zarum L, Meivar-\u00adLevy I, Ferber S (2003) Functional, persistent, and extended liver to pancreas transdifferentiation. J Biol Chem 278:31950\u201331957","journal-title":"J Biol Chem"},{"key":"3_CR72","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.devcel.2009.01.012","volume":"16","author":"V Yechoor","year":"2009","unstructured":"Yechoor V, Liu V, Espiritu C, Paul A, Oka K, Kojima H, Chan L (2009) Neurogenin3 is sufficient for in\u00a0vivo transdetermination of hepatic progenitor cells into islet-like cells but not transdifferentiation of hepatocytes. Dev Cell 16:358\u2013373","journal-title":"Dev Cell"},{"key":"3_CR73","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nature07314","volume":"455","author":"Q Zhou","year":"2008","unstructured":"Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA (2008) In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455:627\u2013632","journal-title":"Nature"},{"key":"3_CR74","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pharmthera.2008.11.009","volume":"121","author":"M Reimann","year":"2009","unstructured":"Reimann M, Bonifacio E, Solimena M, Schwarz PE, Ludwig B, Hanefeld M, Bornstein SR (2009) An update on preventive and regenerative therapies in diabetes mellitus. Pharmacol Ther 121:317\u2013331","journal-title":"Pharmacol Ther"},{"key":"3_CR75","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jdiacomp.2004.12.003","volume":"19","author":"CD Agardh","year":"2005","unstructured":"Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palm\u00e9r M, Harris RA, Robertson JA, Lernmark A (2005) Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19:238\u2013246","journal-title":"J Diabetes Complications"},{"key":"3_CR76","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2337\/dc09-0373","volume":"32","author":"D Bresson","year":"2009","unstructured":"Bresson D, von Herrath M (2009) Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside. Diabetes Care 32:1753\u20131768","journal-title":"Diabetes Care"},{"key":"3_CR77","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00125-009-1371-2","volume":"52","author":"CD Agardh","year":"2009","unstructured":"Agardh CD, Lynch KF, Palm\u00e9r M, Link K, Lernmark A (2009) GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 52:1363\u20131368","journal-title":"Diabetologia"},{"key":"3_CR78","unstructured":"Gottlieb P, Colman PG, Solvason N, Otto K, Roep B, Harrison LC, Isenbarth G, Robinson W, Utz PJ, Steinman L, Garren H, Quan J (2010) One-year results from a phase 1\/2 clinical trial of BHT-3021, a DNA plasmid vaccine for type 1 diabetes (T1D). 70th scientific sessions meeting of the American diabetes association, Orlando, (Abstract 66-OR)"},{"key":"3_CR79","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","volume":"37","author":"RA DeFronzo","year":"1988","unstructured":"DeFronzo RA (1988) The triumvirate: \u03b2-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667\u2013687","journal-title":"Diabetes"},{"key":"3_CR80","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","volume":"58","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo RA (2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773\u2013795","journal-title":"Diabetes"},{"key":"3_CR81","first-page":"80","volume":"18","author":"BA Ramlo-Halsted","year":"2000","unstructured":"Ramlo-Halsted BA, Edelman SV (2000) The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies. Clin Diabetes 18:80\u201384","journal-title":"Clin Diabetes"},{"key":"3_CR82","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/jc.2003-030723","volume":"89","author":"H Bays","year":"2004","unstructured":"Bays H, Mandarino L, DeFronzo RA (2004) Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463\u2013478","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR83","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","volume":"365","author":"M Stumvoll","year":"2005","unstructured":"Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333\u20131346","journal-title":"Lancet"},{"key":"3_CR84","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.amjmed.2006.01.009","volume":"119","author":"KF Petersen","year":"2006","unstructured":"Petersen KF, Shulman GI (2006) Etiology of insulin resistance. Am J Med 119:S10\u2013S16","journal-title":"Am J Med"},{"key":"3_CR85","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4158\/EP.14.5.625","volume":"14","author":"ES Horton","year":"2008","unstructured":"Horton ES (2008) Can newer therapies delay the progression of type 2 diabetes mellitus? Endocrine Pract 14:625\u2013638","journal-title":"Endocrine Pract"},{"key":"3_CR86","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"RC Turner","year":"1999","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK prospective diabetes study (UKPDS) group. JAMA 281:2005\u20132012","journal-title":"JAMA"},{"key":"3_CR87","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jama.291.3.335","volume":"291","author":"SH Saydah","year":"2004","unstructured":"Saydah SH, Fradkin J, Cowie CC (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335\u2013342","journal-title":"JAMA"},{"key":"3_CR88","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O\u2019Neill MC, Zinman B, Viberti G, ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427\u20132443","journal-title":"N Engl J Med"},{"key":"3_CR89","doi-asserted-by":"crossref","first-page":"51B","DOI":"10.1016\/j.amjcard.2006.11.006","volume":"99","author":"GI Uwaifo","year":"2007","unstructured":"Uwaifo GI, Ratner RE (2007) Differential effects of oral hypoglycaemic agents on glucose control and cardiovascular risk. Am J Cardiol 99:51B\u201367B","journal-title":"Am J Cardiol"},{"key":"3_CR90","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","volume":"44","author":"United Kingdom Prospective Diabetes Study Group","year":"1995","unstructured":"United Kingdom Prospective Diabetes Study Group (1995) Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. Diabetes 44:1249\u20131258","journal-title":"Diabetes"},{"key":"3_CR91","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"The ADVANCE Collaborative Group","year":"2008","unstructured":"The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560\u20132572","journal-title":"N Engl J Med"},{"key":"3_CR92","doi-asserted-by":"crossref","unstructured":"Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S (2007) Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2:CD004654. doi:10.1002\/14651858.CD004654.pub2","DOI":"10.1002\/14651858.CD004654.pub2"},{"key":"3_CR93","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.26.3.886","volume":"26","author":"C Hasslacher","year":"2003","unstructured":"Hasslacher C (2003) Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 26:886\u2013891","journal-title":"Diabetes Care"},{"key":"3_CR94","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1262-3636(07)70257-4","volume":"32","author":"JF Blickl\u00e9","year":"2006","unstructured":"Blickl\u00e9 JF (2006) Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab 32:113\u2013120","journal-title":"Diabetes Metab"},{"key":"3_CR95","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1520-7560(200003\/04)16:2<125::AID-DMRR90>3.0.CO;2-4","volume":"16","author":"A Ceriello","year":"2000","unstructured":"Ceriello A (2000) The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 16:125\u2013132","journal-title":"Diabetes Metab Res Rev"},{"key":"3_CR96","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","volume":"137","author":"D Kirpichnikov","year":"2002","unstructured":"Kirpichnikov D, McFarlane SI, Sowers JR (2002) Metformin: an update. Ann Intern Med 137:25\u201333","journal-title":"Ann Intern Med"},{"key":"3_CR97","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1210\/jc.2003-030178","volume":"88","author":"P Dandona","year":"2003","unstructured":"Dandona P, Aljada A, Chaudhuri A, Bandyopadhyay A (2003) The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-\u00adrelated complications in type 2 diabetes. J Clin Endocrinol Metab 88:2422\u20132429","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR98","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S0022-3565(25)24016-2","volume":"271","author":"S Verma","year":"1994","unstructured":"Verma S, Bhanot S, McNeill JH (1994) Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. J Pharmacol Exp Ther 271:1334\u20131337","journal-title":"J Pharmacol Exp Ther"},{"key":"3_CR99","doi-asserted-by":"crossref","first-page":"6S71","DOI":"10.1016\/S1262-3636(03)72790-6","volume":"29","author":"JC Mamputu","year":"2003","unstructured":"Mamputu JC, Wiernsperger NF, Renier G (2003) Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29:6S71\u20136S76","journal-title":"Diabetes Metab"},{"key":"3_CR100","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S1262-3636(03)72787-6","volume":"29","author":"PJ Grant","year":"2003","unstructured":"Grant PJ (2003) Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29:644\u2013652","journal-title":"Diabetes Metab"},{"key":"3_CR101","unstructured":"Bristol-Myers Squibb Company. Glucophage (metformin hydrochloride tablets); Glucophage XR (metformin hydrochloride extended-release tablets). Available at: http:\/\/packageinserts.bms.com\/pi\/pi_glucophage.pdf. Accessed 10 Jan 2013"},{"key":"3_CR102","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/archinte.166.18.1975","volume":"166","author":"RZ Ting","year":"2006","unstructured":"Ting RZ, Szeto CC, Chan MH (2006) Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med 166:1975\u20131979","journal-title":"Arch Intern Med"},{"key":"3_CR103","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","volume":"351","author":"H Yki-Jarvinen","year":"2004","unstructured":"Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106\u20131118","journal-title":"N Engl J Med"},{"key":"3_CR104","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.mjt.0000212890.82339.8d","volume":"14","author":"I Ahmed","year":"2007","unstructured":"Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ (2007) Dual PPAR \u03b1\/\u03b3 agonists: promises and pitfalls in type 2 diabetes. Am J Ther 14:49\u201362","journal-title":"Am J Ther"},{"key":"3_CR105","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00125-004-1436-1","volume":"47","author":"JM Ye","year":"2004","unstructured":"Ye JM, Dzamko N, Cleasby ME, Hegarty BD, Furler SM, Cooney GJ, Kraegen EW (2004) Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 47:1306\u20131313","journal-title":"Diabetologia"},{"key":"3_CR106","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","volume":"51","author":"TA Buchanan","year":"2002","unstructured":"Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP (2002) Preservation of pancreatic \u03b2-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796\u20132803","journal-title":"Diabetes"},{"key":"3_CR107","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","volume":"55","author":"AH Xiang","year":"2006","unstructured":"Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Kawakubo M, Buchanan TA (2006) Effect of pioglitazone on pancreatic \u03b2-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55:517\u2013522","journal-title":"Diabetes"},{"key":"3_CR108","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","volume":"23","author":"S Aronoff","year":"2000","unstructured":"Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL (2000) Pioglitazone hydrochloride monotherapy improves glycaemic control in the treatment of patients with type 2 diabetes: a 6- month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23:1605\u20131611","journal-title":"Diabetes Care"},{"key":"3_CR109","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2337\/diacare.24.2.308","volume":"24","author":"LS Phillips","year":"2001","unstructured":"Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A, Rosiglitazone Clinical Trials Study Group (2001) Once- and twice-daily dosing with rosiglitazone improves glycaemic control in patients with type 2 diabetes. Rosiglitazone Clinical Trial Study Group. Diabetes Care 24:308\u2013315","journal-title":"Diabetes Care"},{"key":"3_CR110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/VHRM.S936","volume":"3","author":"JM Stafford","year":"2007","unstructured":"Stafford JM, Elasy T (2007) Treatment update: thiazolinediones in combination with metformin for the treatment of type 2 diabetes. Vasc Health Risk Manag 3:503\u2013510","journal-title":"Vasc Health Risk Manag"},{"key":"3_CR111","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0002-9343(01)00713-6","volume":"111","author":"MS Kipnes","year":"2001","unstructured":"Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL (2001) Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 111:10\u201317","journal-title":"Am J Med"},{"key":"3_CR112","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2337\/diacare.24.7.1226","volume":"24","author":"P Raskin","year":"2001","unstructured":"Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J (2001) A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24:1226\u20131232","journal-title":"Diabetes Care"},{"key":"3_CR113","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1211\/jpp.60.12.0002","volume":"60","author":"JC Waksman","year":"2008","unstructured":"Waksman JC (2008) Cardiovascular risk of rosiglitazone: another perspective. J Pharm Pharmacol 60:1573\u20131582","journal-title":"J Pharm Pharmacol"},{"key":"3_CR114","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1472-8206.2008.00568.x","volume":"22","author":"PA Sarafidis","year":"2008","unstructured":"Sarafidis PA, Pantelis A (2008) Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. Fundam Clin Pharmacol 22:247\u2013264","journal-title":"Fundam Clin Pharmacol"},{"key":"3_CR115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0149-2918(04)90017-3","volume":"26","author":"T Meriden","year":"2004","unstructured":"Meriden T (2004) Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 26:177\u2013190","journal-title":"Clin Ther"},{"key":"3_CR116","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ecl.2004.04.003","volume":"33","author":"D Einhorn","year":"2004","unstructured":"Einhorn D, Aroda VR, Henry RR (2004) Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am 33:595\u2013616","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3_CR117","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","volume":"11","author":"Y Guan","year":"2005","unstructured":"Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD (2005) Thiazolidinediones expand body fluid volume through PPAR gamma stimulation of EnaC-mediated renal salt absorption. Nat Med 11:861\u2013866","journal-title":"Nat Med"},{"key":"3_CR118","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","volume":"108","author":"RW Nesto","year":"2003","unstructured":"Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R, American Heart Association; American Diabetes Association (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108:2941\u20132948","journal-title":"Circulation"},{"key":"3_CR119","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1345\/aph.1E072","volume":"38","author":"TR Marcy","year":"2004","unstructured":"Marcy TR, Britton ML, Blevins SM (2004) Second-generation thiazolinediones and hepatotoxicity. Ann Pharmacother 38:1419\u20131423","journal-title":"Ann Pharmacother"},{"key":"3_CR120","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1001\/archinte.168.19.2070","volume":"168","author":"E Selvin","year":"2008","unstructured":"Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL (2008) Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 168:2070\u20132080","journal-title":"Arch Intern Med"},{"key":"3_CR121","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14740338.7.5.579","volume":"7","author":"S Singh","year":"2008","unstructured":"Singh S, Loke YK (2008) The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf 7:579\u2013585","journal-title":"Expert Opin Drug Saf"},{"key":"3_CR122","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00198-007-0477-y","volume":"19","author":"A Grey","year":"2008","unstructured":"Grey A (2008) Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19:129\u2013137","journal-title":"Osteoporos Int"},{"key":"3_CR123","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archinte.168.8.820","volume":"168","author":"C Meier","year":"2008","unstructured":"Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820\u2013825","journal-title":"Arch Intern Med"},{"key":"3_CR124","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1464-5491.2008.02491.x","volume":"25","author":"E Liazos","year":"2008","unstructured":"Liazos E, Broadbent DM, Beare N, Kumar N (2008) Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones. Diabet Med 25:860\u2013862","journal-title":"Diabet Med"},{"key":"3_CR125","first-page":"311","volume":"24","author":"AJ Scheen","year":"1998","unstructured":"Scheen AJ (1998) Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metab 24:311\u2013320","journal-title":"Diabetes Metab"},{"key":"3_CR126","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003495-200565030-00005","volume":"65","author":"AJ Krentz","year":"2005","unstructured":"Krentz AJ, Bailey CJ (2005) Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65:385\u2013411","journal-title":"Drugs"},{"key":"3_CR127","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","volume":"359","author":"JL Chiasson","year":"2002","unstructured":"Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-\u00adNIDDM randomised trial. Lancet 359:2072\u20132077","journal-title":"Lancet"},{"key":"3_CR128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diacare.28.1.154","volume":"28","author":"FA Laar van de","year":"2005","unstructured":"van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C (2005) Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 28:154\u2013163","journal-title":"Diabetes Care"},{"key":"3_CR129","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/pgmj.2008.067926","volume":"85","author":"W Crasto","year":"2009","unstructured":"Crasto W, Jarvis J, Khunti K, Davies MJ (2009) New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J 85:257\u2013267","journal-title":"Postgrad Med J"},{"key":"3_CR130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2337\/diacare.16.1.21","volume":"16","author":"RR Henry","year":"1993","unstructured":"Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS (1993) Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 16:21\u201331","journal-title":"Diabetes Care"},{"key":"3_CR137","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","volume":"297","author":"JJ Holst","year":"2009","unstructured":"Holst JJ, Vilsb\u00f8ll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127\u2013136","journal-title":"Mol Cell Endocrinol"},{"key":"3_CR296","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.13.S1.1","volume":"13","author":"American Association of Clinical Endocrinologists","year":"2007","unstructured":"American Association of Clinical Endocrinologists (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13:1\u201368","journal-title":"Endocr Pract"},{"key":"3_CR136","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131\u20132157","journal-title":"Gastroenterology"},{"key":"3_CR139","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4158\/EP.14.3.285","volume":"14","author":"CA Sheffield","year":"2008","unstructured":"Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA (2008) Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 14:285\u2013292","journal-title":"Endocr Pract"},{"key":"3_CR131","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncpendmet0017","volume":"1","author":"DJ Drucker","year":"2005","unstructured":"Drucker DJ (2005) Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 1:22\u201331","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"3_CR132","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1517\/14656566.8.15.2593","volume":"8","author":"A Barnett","year":"2007","unstructured":"Barnett A (2007) Exenatide. Expert Opin Pharmacother 8:2593\u20132608","journal-title":"Expert Opin Pharmacother"},{"key":"3_CR133","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","volume":"40","author":"AM Lambeir","year":"2003","unstructured":"Lambeir AM, Durinx C, Scharp\u00e9 S, De Meester I (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:209\u2013294","journal-title":"Crit Rev Clin Lab Sci"},{"key":"3_CR134","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/030079908X219661","volume":"24","author":"AJ Krentz","year":"2008","unstructured":"Krentz AJ (2008) Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. Curr Med Res Opin 24:401\u2013417","journal-title":"Curr Med Res Opin"},{"key":"3_CR135","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","volume":"113","author":"ME Doyle","year":"2007","unstructured":"Doyle ME, Egan JM (2007) Mechanisms of action of glucagons like peptide 1 in the pancreas. Pharmacol Ther 113:546\u2013593","journal-title":"Pharmacol Ther"},{"key":"3_CR138","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.2165\/11201060-000000000-00000","volume":"69","author":"KF Croom","year":"2009","unstructured":"Croom KF, McCormack PL (2009) Liraglutide: a review of its use in type 2 diabetes mellitus. Drugs 69:1985\u20132004","journal-title":"Drugs"},{"key":"3_CR140","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","volume":"143","author":"RJ Heine","year":"2005","unstructured":"Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143:559\u2013569","journal-title":"Ann Intern Med"},{"key":"3_CR141","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","volume":"28","author":"DM Kendall","year":"2005","unstructured":"Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083\u20131091","journal-title":"Diabetes Care"},{"key":"3_CR142","unstructured":"U.S. Food and Drug Administration (2008) Information for healthcare professionals: exenatide (marketed as Byetta). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124713.htm. Accessed 10 Jan 2013"},{"key":"3_CR143","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc07-0233","volume":"30","author":"B Ahren","year":"2007","unstructured":"Ahren B (2007) Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 30:1344\u20131350","journal-title":"Diabetes Care"},{"key":"3_CR144","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2174\/138955708784567421","volume":"8","author":"C Hale","year":"2008","unstructured":"Hale C, Wang M (2008) Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem 8:702\u2013710","journal-title":"Mini Rev Med Chem"},{"key":"3_CR145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","volume":"1492","author":"T Nishimura","year":"2000","unstructured":"Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203\u2013206","journal-title":"Biochim Biophys Acta"},{"key":"3_CR146","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627\u20131635","journal-title":"J Clin Invest"},{"key":"3_CR147","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","volume":"148","author":"A Kharitonenkov","year":"2007","unstructured":"Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774\u2013781","journal-title":"Endocrinology"},{"key":"3_CR148","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","volume":"149","author":"T Coskun","year":"2008","unstructured":"Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018\u20136027","journal-title":"Endocrinology"},{"key":"3_CR149","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","volume":"59","author":"FM Fisher","year":"2010","unstructured":"Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781\u20132789","journal-title":"Diabetes"},{"key":"3_CR150","first-page":"375","volume":"22","author":"S Edelman","year":"2008","unstructured":"Edelman S, Maier H, Wilhelm K (2008) Pramlintide in the treatment of diabetes mellitus. Bio Drugs 22:375\u2013386","journal-title":"Bio Drugs"},{"key":"3_CR151","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1185\/030079908X253537","volume":"24","author":"C Wysham","year":"2008","unstructured":"Wysham C, Lush C, Zhang B, Maier H, Wilhelm K (2008) Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin 24:79\u201385","journal-title":"Curr Med Res Opin"},{"key":"3_CR152","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc11-0064","volume":"34","author":"RA Defronzo","year":"2011","unstructured":"Defronzo RA (2011) Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 34:789\u2013794","journal-title":"Diabetes Care"},{"key":"3_CR153","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6823-7-3","volume":"7","author":"RE Scranton","year":"2007","unstructured":"Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A (2007) A randomized, double-\u00adblind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord 7:3","journal-title":"BMC Endocr Disord"},{"key":"3_CR154","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clinthera.2007.01.003","volume":"29","author":"FJ Zieve","year":"2007","unstructured":"Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL (2007) Results of the glucose-\u00adlowering effect of WelChol study (GLOWS): a randomized, double-blind placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycaemic control in subjects with type 2 diabetes. Clin Ther 29:74\u201383","journal-title":"Clin Ther"},{"key":"3_CR155","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1126\/science.320.5875.438","volume":"320","author":"J Couzin","year":"2008","unstructured":"Couzin J (2008) Medicine: bypassing medicine to treat diabetes. Science 320:438\u2013440","journal-title":"Science"},{"key":"3_CR156","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.amjmed.2008.09.041","volume":"122","author":"H Buchwald","year":"2009","unstructured":"Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-\u00adanalysis. Am J Med 122:248\u2013256.e5","journal-title":"Am J Med"},{"key":"3_CR157","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev.med.051308.105148","volume":"61","author":"F Rubino","year":"2010","unstructured":"Rubino F, Schauer PR, Kaplan LM, Cummings DE (2010) Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 61:393\u2013411","journal-title":"Annu Rev Med"},{"key":"3_CR158","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MED.0b013e32832912e7","volume":"16","author":"KJ Frachettia","year":"2009","unstructured":"Frachettia KJ, Goldfine AB (2009) Bariatric surgery for diabetes management. Curr Opin Endocrinol Diabetes Obes 16:119\u2013124","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"3_CR159","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.soard.2008.04.001","volume":"4","author":"H Buchwald","year":"2008","unstructured":"Buchwald H (2008) Introduction and current status of bariatric procedures. Surg Obes Relat Dis 4:S1\u2013S6","journal-title":"Surg Obes Relat Dis"},{"key":"3_CR160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-150-2-200901200-00007","volume":"150","author":"ML Vetter","year":"2009","unstructured":"Vetter ML, Cardillo S, Rickels MR, Iqbal N (2009) Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 150:94\u2013103","journal-title":"Ann Intern Med"},{"key":"3_CR161","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1381\/0960892053923789","volume":"15","author":"GH Ballantyne","year":"2005","unstructured":"Ballantyne GH, Gumbs A, Modlin IM (2005) Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg 15:692\u2013699","journal-title":"Obes Surg"},{"key":"3_CR162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.sla.0000102989.54824.fc","volume":"239","author":"F Rubino","year":"2004","unstructured":"Rubino F, Marescaux J (2004) Effect of duodenal-jejunal exclusion in a non-obese animal model of T2DM: a new perspective for an old disease. Ann Surg 239:1\u201311","journal-title":"Ann Surg"},{"key":"3_CR163","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.2337\/dc08-s271","volume":"31","author":"F Rubino","year":"2008","unstructured":"Rubino F (2008) Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 31:S290\u2013S296","journal-title":"Diabetes Care"},{"key":"3_CR164","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s00125-009-1511-8","volume":"52","author":"FK Knop","year":"2009","unstructured":"Knop FK (2009) Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia 52:2270\u20132276","journal-title":"Diabetologia"},{"key":"3_CR165","doi-asserted-by":"crossref","first-page":"E447","DOI":"10.1152\/ajpendo.00153.2004","volume":"288","author":"AD Strader","year":"2005","unstructured":"Strader AD, Vahl TP, Jandacek RJ, Woods SC, D\u2019Alessio DA, Seeley RJ (2005) Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 288:E447\u2013E453","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3_CR166","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1210\/jc.2004-1076","volume":"90","author":"J Korner","year":"2005","unstructured":"Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL, Wardlaw SL (2005) Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90:359\u2013365","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR167","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1210\/jc.2005-0904","volume":"91","author":"R Mor\u00ednigo","year":"2006","unstructured":"Mor\u00ednigo R, Moiz\u00e9 V, Musri M, Lacy AM, Navarro S, Mar\u00edn JL, Delgado S, Casamitjana R, Vidal J (2006) Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91:1735\u20131740","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR168","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.2337\/dc09-2107","volume":"33","author":"JM Isbell","year":"2010","unstructured":"Isbell JM, Tamboli RA, Hansen EN, Saliba J, Dunn JP, Phillips SE, Marks-Shulman PA, Abumrad NN (2010) The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care 33:1438\u20131442","journal-title":"Diabetes Care"},{"key":"3_CR169","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.2337\/db10-0253","volume":"59","author":"JP Furet","year":"2010","unstructured":"Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Dor\u00e9 J, Henegar C, Rizkalla S, Cl\u00e9ment K (2010) Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59:3049\u20133057","journal-title":"Diabetes"},{"key":"3_CR170","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.2337\/diabetes.51.10.2959","volume":"51","author":"JA Houmard","year":"2002","unstructured":"Houmard JA, Tanner CJ, Yu C, Cunningham PG, Pories WJ, MacDonald KG, Shulman GI (2002) Effect of weight loss on insulin sensitivity and intramuscular long-chain fatty acyl-\u00adCoAs in morbidly obese subjects. Diabetes 51:2959\u20132963","journal-title":"Diabetes"},{"key":"3_CR171","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1185\/03007990802212981","volume":"24","author":"RR Henry","year":"2008","unstructured":"Henry RR (2008) Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. Curr Med Res Opin 24:2189\u20132202","journal-title":"Curr Med Res Opin"},{"key":"3_CR172","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1742-1241.2008.01980.x","volume":"63","author":"J Philippe","year":"2009","unstructured":"Philippe J, Raccah D (2009) Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract 63:321\u2013332","journal-title":"Int J Clin Pract"},{"key":"3_CR173","first-page":"503","volume":"12","author":"M Christensen","year":"2009","unstructured":"Christensen M, Knop FK, Holst JJ, Vilsboll T (2009) Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 12:503\u2013513","journal-title":"IDrugs"},{"key":"3_CR174","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.phrs.2007.03.002","volume":"56","author":"P Balakumar","year":"2007","unstructured":"Balakumar P, Rose M, Ganti SS, Krishan P, Singh M (2007) PPAR dual agonists: are they opening Pandora\u2019s Box? Pharmacol Res 56:91\u201398","journal-title":"Pharmacol Res"},{"key":"3_CR175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(09)60870-9","volume":"374","author":"RR Henry","year":"2009","unstructured":"Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M (2009) Effect of the dual peroxisome proliferator-activated receptor \u03b1\/\u03b3: results from SYNCHRONY, a phase II, randomised, dose-ranging study in patients with type 2 diabetes. Lancet 374:126\u2013135","journal-title":"Lancet"},{"key":"3_CR176","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1677\/JOE-08-0453","volume":"201","author":"H Lan","year":"2009","unstructured":"Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A, Abbondanzo SJ, Hu W, Yang S, Ning Y, Del Vecchio RA, Poulet F, Laverty M, Gustafson EL, Hedrick JA, Kowalski TJ (2009) GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 201:219\u2013230","journal-title":"J Endocrinol"},{"key":"3_CR177","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2337\/db08-1237","volume":"58","author":"LM Lauffer","year":"2009","unstructured":"Lauffer LM, Iakoubov R, Brubaker PL (2009) GPR119 Is essential for oleoylethanolamide-\u00adinduced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58:1058\u20131066","journal-title":"Diabetes"},{"key":"3_CR178","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1210\/en.2008-0182","volume":"149","author":"L Lauffer","year":"2008","unstructured":"Lauffer L, Iakoubov R, Brubaker PL (2008) GPR119: \u201cdouble-dipping\u201d for better glycaemic control. Endocrinology 149:2035\u20132037","journal-title":"Endocrinology"},{"key":"3_CR179","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1517\/13543770903153878","volume":"19","author":"RM Jones","year":"2009","unstructured":"Jones RM, Leonard JN, Buzard DJ, Lehmann J (2009) GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat 19:1339\u20131359","journal-title":"Expert Opin Ther Pat"},{"key":"3_CR180","unstructured":"Positive results from Metabolex\u2019 Phase 1 MBX-2982 clinical trial for treating type 2 diabetes. News-Medical.Net. http:\/\/www.news-medical.net\/news\/20091014\/Positive-results-from-Metabolex-Phase-1-MBX-2982-clinical-trial-for-treating-type-2-diabetes.aspx. Accessed 10 Jan 2013"},{"key":"3_CR181","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","volume":"356","author":"CM Larsen","year":"2007","unstructured":"Larsen CM, Faulenbach M, Vaag A, V\u00f8lund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY (2007) Interleukin-1\u2013receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517\u20131526","journal-title":"N Engl J Med"},{"key":"3_CR182","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ncpendmet0783","volume":"4","author":"MY Donath","year":"2008","unstructured":"Donath MY, Mandrup-Poulsen T (2008) The use of interleukin- 1-receptor antagonists in the treatment of diabetes mellitus. Nat Rev Endocrinol 4:240\u2013241","journal-title":"Nat Rev Endocrinol"},{"key":"3_CR183","unstructured":"Donath MY, Weder C, Brunner A, Keller C, Whitmore J, Der K, Zayed H, Scannon PJ, Feldstein JD, Dinarello CA, Solinger AM (2009) XOMA 052, a potential disease modifying anti-IL-1beta antibody, shows sustained HbA1c reductions 3 months after a single injection with no increases in safety parameters in subjects with type 2 diabetes. Proc 69th scientific sessions meeting of the American diabetes association, New Orleans, (Abstract 113-OR)"},{"key":"3_CR184","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/dia.2009.0013","volume":"11","author":"DE Vaughn","year":"2009","unstructured":"Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI (2009) Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 11:345\u2013352","journal-title":"Diabetes Technol Ther"},{"key":"3_CR185","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2337\/dc10-1892","volume":"34","author":"M Hompesch","year":"2011","unstructured":"Hompesch M, Muchmore DB, Morrow L, Vaughn DE (2011) Accelerated insulin pharmacokinetics and improved postprandial glycaemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care 34:666\u2013668","journal-title":"Diabetes Care"},{"key":"3_CR186","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ddrr.20","volume":"14","author":"JCG Halford","year":"2008","unstructured":"Halford JCG, Harrold JA (2008) Neuropharmacology of human appetite expression. Dev Disabil Res Rev 14:158\u2013164","journal-title":"Dev Disabil Res Rev"},{"key":"3_CR187","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"SR Smith","year":"2010","unstructured":"Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 363:245\u2013256","journal-title":"N Engl J Med"},{"key":"3_CR188","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1358\/dof.2008.033.09.1251351","volume":"33","author":"P Cole","year":"2008","unstructured":"Cole P, Vicente M, Castaner R (2008) Dapagliflozin: SGLT2 inhibitor antidiabetic agent. Drug Future 33:745\u2013751","journal-title":"Drug Future"},{"key":"3_CR189","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2008.01829.x","volume":"62","author":"SA Jabbour","year":"2008","unstructured":"Jabbour SA, Goldstein BJ (2008) Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 62:1279\u20131284","journal-title":"Int J Clin Pract"},{"key":"3_CR190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","volume":"11","author":"I Idris","year":"2009","unstructured":"Idris I, Donnelly R (2009) Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 11:79\u201388","journal-title":"Diabetes Obes Metab"},{"key":"3_CR191","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbamcr.2003.09.001","volume":"1643","author":"A Ikari","year":"2003","unstructured":"Ikari A, Nakano M, Ishibashi M, Kawano K, Suketa Y, Harada H, Takagi K (2003) Recovery from heat shock injury by activation of Na+-glucose cotransporter in renal epithelial cells. Biochim Biophys Acta 1643:47\u201353","journal-title":"Biochim Biophys Acta"},{"key":"3_CR192","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.bjp.0703829","volume":"132","author":"K Arakawa","year":"2001","unstructured":"Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, Saito A (2001) Improved diabetic syndrome in C57BL\/KsJ-db\/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132:578\u2013586","journal-title":"Br J Pharmacol"},{"key":"3_CR193","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.108.146589","volume":"328","author":"S Vemula","year":"2009","unstructured":"Vemula S, Roder KE, Yang T, Bhat GJ, Thekkumkara TJ, Abbruscato TJ (2009) A functional role for sodium dependent glucose transport across the blood-brain barrier during oxygen glucose deprivation. J Pharmacol Exp Ther 328:487\u2013495","journal-title":"J Pharmacol Exp Ther"},{"key":"3_CR194","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","volume":"90","author":"L Zhou","year":"2003","unstructured":"Zhou L, Cryan EV, D\u2019Andrea MR, Belkowski S, Conway BR, Demarest KT (2003) Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1). J Cell Biochem 90:339\u2013346","journal-title":"J Cell Biochem"},{"key":"3_CR195","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","volume":"57","author":"S Han","year":"2008","unstructured":"Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM (2008) Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57:1723\u20131729","journal-title":"Diabetes"},{"key":"3_CR196","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1345\/aph.1M212","volume":"43","author":"AM Brooks","year":"2009","unstructured":"Brooks AM, Thacker SM (2009) Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 43:1286\u20131293","journal-title":"Ann Pharmacother"},{"key":"3_CR197","unstructured":"Johnson & Johnson Pharmaceutical Research & Development, LLC (2010) CANagliflozin treatment and trial analysis-sulfonylurea (CANTATA-SU) SGLT2 add-on to metformin versus glimepiride. ClinicalTrials.gov Idenitifier: NCT00968812. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00968812?term=canagliflozin&rank=5. Accessed 10 Jan 2013"},{"key":"3_CR198","unstructured":"Johnson & Johnson Pharmaceutical Research & Development, LLC (2010) The CANTATA-M (CANagliflozin treatment and trial analysis\u2014monotherapy) trial. ClinicalTrials.gov Idenitifier: NCT01081834. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01081834?term=canagliflozin&rank=2. Accessed 10 Jan 2013"},{"key":"3_CR199","unstructured":"Johnson & Johnson Pharmaceutical Research & Development, LLC (2010) The CANTATA-\u00adMSU trial (Canagliflozin treatment and trial analysis\u2014metformin and sulphonylurea). ClinicalTrials.gov Idenitifier: NCT01106625. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01106625?term=canagliflozin&rank=3. Accessed 10 Jan 2013"},{"key":"3_CR200","unstructured":"Johnson & Johnson Pharmaceutical Research & Development, LLC (2010) The CANTATA-D trial (Canagliflozin treatment and trial analysis\u2014DPP-4 inhibitor comparator trial). ClinicalTrials.gov. Idenitifier: NCT01106677. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01106677?term=canagliflozin&rank=4. Accessed 10 Jan 2013"},{"key":"3_CR201","unstructured":"Bhanot S, Murray SF, Booten SL, Chakravarty K, Zanardi T, Henry S, Watts LM, Wancewicz EV, Siwkowski A, Monia BP (2009) ISIS 388626, an SGLT2 antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well-tolerated. Proc 69th scientific sessions meeting of the American diabetes association, New Orleans, (Abstract 328-OR)"},{"key":"3_CR202","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2337\/db05-1060","volume":"55","author":"SA Price","year":"2006","unstructured":"Price SA, Dent C, Duran-Jimenez B, Liang Y, Zhang L, Rebar EJ, Case CC, Gregory PD, Martin TJ, Spratt SK, Tomlinson DR (2006) Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes 55:1847\u20131854","journal-title":"Diabetes"},{"key":"3_CR203","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/sj.gt.3302985","volume":"14","author":"CL Dent","year":"2007","unstructured":"Dent CL, Lau G, Drake EA, Yoon A, Case CC, Gregory PD (2007) Regulation of endogenous gene expression using small molecule-controlled engineered zinc-finger protein transcription factors. Gene Ther 14:1362\u20131369","journal-title":"Gene Ther"},{"key":"3_CR204","unstructured":"Benaim E, Hamilton S, Spratt K, Giedlin M, Kim H, Ando D; Sangamo DN Study Group (2009) Vascular endothelial growth factor zinc finger protein activator (SB-509) in mild to moderate diabetic peripheral neuropathy patients. Interim phase 2 results (SB-509-0601 study). Proc 69th scientific sessions meeting of the American diabetes association, New Orleans, (Abstract 859-P)"},{"key":"3_CR205","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/sj.ijo.0803677","volume":"31","author":"L Alberti","year":"2007","unstructured":"Alberti L, Girola A, Gilardini L, Conti A, Cattaldo S, Micheletto G, Invitti C (2007) Type 2 diabetes and metabolic syndrome are associated with increased expression of 11-\u03b2-hydroxysteroid dehydrogenase 1 in obese subjects. Int J Obes 31:1826\u20131831","journal-title":"Int J Obes"},{"key":"3_CR206","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2337\/dc09-2315","volume":"33","author":"J Rosenstock","year":"2010","unstructured":"Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R, INCB13739\u2013202 Principal Investigators (2010) The 11-\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor INCB-13739 improves hyperglycaemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33:1516\u20131522","journal-title":"Diabetes Care"},{"key":"3_CR207","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1021\/jm0600794","volume":"49","author":"D Schuster","year":"2006","unstructured":"Schuster D, Maurer EM, Laggner C, Nashev LG, Wilckens T, Langer T, Odermatt A (2006) The discovery of new 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modelling and virtual screening. J Med Chem 49:3454\u20133466","journal-title":"J Med Chem"},{"key":"3_CR208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33549\/physiolres.931610","volume":"58","author":"I Dost\u00e1lov\u00e1","year":"2009","unstructured":"Dost\u00e1lov\u00e1 I, Haluz\u00edkov\u00e1 D, Haluz\u00edk M (2009) Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity\/type 2 diabetes mellitus. Physiol Res 58:1\u20137","journal-title":"Physiol Res"},{"key":"3_CR209","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0904187106","volume":"106","author":"MJ Potthoff","year":"2009","unstructured":"Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, Mohammadi M, Finck BN, Mangelsdorf DJ, Kliewer SA, Burgess SC (2009) FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 106:10853\u201310858","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR210","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.2337\/db08-1775","volume":"58","author":"K Mai","year":"2009","unstructured":"Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M, Meinus S, Reinecke F, M\u00f6hlig M, Weickert MO, Clemenz M, Pfeiffer AF, Kintscher U, Spuler S, Spranger J (2009) Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor\u201321. Diabetes 58:1532\u20131538","journal-title":"Diabetes"},{"key":"3_CR211","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cmet.2009.03.012","volume":"9","author":"BB Zhang","year":"2009","unstructured":"Zhang BB, Zhou G, Li C (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9:407\u2013416","journal-title":"Cell Metab"},{"key":"3_CR212","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1210\/er.2005-0005","volume":"26","author":"T Kadowaki","year":"2005","unstructured":"Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439\u2013451","journal-title":"Endocr Rev"},{"key":"3_CR213","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.2337\/dc06-0952","volume":"29","author":"MB Snijder","year":"2006","unstructured":"Snijder MB, Heine RJ, Seidell JC, Bouter LM, Stehouwer CD, Nijpels G, Funahashi T, Matsuzawa Y, Shimomura I, Dekker JM (2006) Associations of adiponectin with incident impaired glucose metabolism and type 2 diabetes in older men and women. Diabetes Care 29:2498\u20132503","journal-title":"Diabetes Care"},{"key":"3_CR214","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1042\/BST0340798","volume":"34","author":"X Fang","year":"2006","unstructured":"Fang X, Sweeney G (2006) Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochem Soc Trans 34:798\u2013801","journal-title":"Biochem Soc Trans"},{"key":"3_CR215","doi-asserted-by":"crossref","first-page":"251S","DOI":"10.3945\/ajcn.2009.28449A","volume":"91","author":"GL Blackburn","year":"2010","unstructured":"Blackburn GL (2010) From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor c modulators. Am J Clin Nutr 91:251S\u2013253S","journal-title":"Am J Clin Nutr"},{"key":"3_CR216","doi-asserted-by":"crossref","first-page":"262S","DOI":"10.3945\/ajcn.2009.28449D","volume":"91","author":"WW Cheatham","year":"2010","unstructured":"Cheatham WW (2010) Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr 91:262S\u2013266S","journal-title":"Am J Clin Nutr"},{"key":"3_CR217","doi-asserted-by":"crossref","first-page":"267S","DOI":"10.3945\/ajcn.2009.28449E","volume":"91","author":"LS Higgins","year":"2010","unstructured":"Higgins LS, DePaoli AM (2010) Selective peroxisome proliferator-activated receptor c (PPARc) modulation as a strategy for safer therapeutic PPARc activation. Am J Clin Nutr 91:267S\u2013272S","journal-title":"Am J Clin Nutr"},{"key":"3_CR218","doi-asserted-by":"crossref","first-page":"258S","DOI":"10.3945\/ajcn.2009.28449C","volume":"91","author":"F Ziemke","year":"2010","unstructured":"Ziemke F, Mantzoros CS (2010) Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 91:258S\u2013261S","journal-title":"Am J Clin Nutr"},{"key":"3_CR219","first-page":"641","volume":"21","author":"T Billyard","year":"2007","unstructured":"Billyard T, McTernan P, Kumar S (2007) Potential therapies based on antidiabetic peptides. Clin Endocrinol Metab 21:641\u2013655","journal-title":"Clin Endocrinol Metab"},{"key":"3_CR220","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cmet.2006.05.005","volume":"3","author":"B Cool","year":"2006","unstructured":"Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R, Zhao G, Marsh K, Kym P, Jung P, Camp HS, Frevert E (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3:403\u2013416","journal-title":"Cell Metab"},{"key":"3_CR221","doi-asserted-by":"crossref","first-page":"32549","DOI":"10.1074\/jbc.M706536200","volume":"282","author":"O Goransson","year":"2007","unstructured":"Goransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M, Viollet B, Hardie DG, Sakamoto K (2007) Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 282:32549\u201332560","journal-title":"J Biol Chem"},{"key":"3_CR222","doi-asserted-by":"crossref","first-page":"32539","DOI":"10.1074\/jbc.M706543200","volume":"282","author":"MJ Sanders","year":"2007","unstructured":"Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D (2007) Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 282:32539\u201332548","journal-title":"J Biol Chem"},{"key":"3_CR223","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.febslet.2008.06.044","volume":"582","author":"D Moreno","year":"2008","unstructured":"Moreno D, Knecht E, Viollet B, Sanz P (2008) A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-\u00adindependent mechanism. FEBS Lett 582:2650\u20132654","journal-title":"FEBS Lett"},{"key":"3_CR224","doi-asserted-by":"crossref","first-page":"16051","DOI":"10.1074\/jbc.M710114200","volume":"283","author":"T Pang","year":"2008","unstructured":"Pang T, Zhang ZS, Gu M, Qiu BY, Yu LF, Cao PR, Shao W, Su MB, Li JY, Nan FJ, Li J (2008) Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J Biol Chem 283:16051\u201316060","journal-title":"J Biol Chem"},{"key":"3_CR225","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1101\/gad.1467506","volume":"20","author":"MC Haigis","year":"2006","unstructured":"Haigis MC, Guarente LP (2006) Mammalian sirtuins \u2014emerging roles in physiology, aging, and calorie restriction. Genes Dev 20:2913\u20132921","journal-title":"Genes Dev"},{"key":"3_CR226","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nature06261","volume":"450","author":"JC Milne","year":"2007","unstructured":"Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712\u2013716","journal-title":"Nature"},{"key":"3_CR227","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1128\/MCB.00705-08","volume":"29","author":"T Yoshizaki","year":"2008","unstructured":"Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, Babendure JL, Lu JC, Smith JJ, Jirousek MR, Olefsky JM (2008) SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 29:1363\u20131374","journal-title":"Mol Cell Biol"},{"key":"3_CR228","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.yjmcc.2007.08.008","volume":"43","author":"H Ota","year":"2007","unstructured":"Ota H, Akishita M, Eto M, Iijima K, Kaneki M, Ouchi Y (2007) Sirt1 modulates premature senescencelike phenotype in human endothelial cells. J Mol Cell Cardiol 43:571\u2013579","journal-title":"J Mol Cell Cardiol"},{"key":"3_CR229","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/cvr\/cvn224","volume":"80","author":"QJ Zhang","year":"2008","unstructured":"Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, Wei YS, Cai H, Liu DP, Liang CC (2008) Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 80:191\u2013199","journal-title":"Cardiovasc Res"},{"key":"3_CR230","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3181\/00379727-232-2320814","volume":"232","author":"JW Rush","year":"2007","unstructured":"Rush JW, Quadrilatero J, Levy AS, Ford RJ (2007) Chronic resveratrol enhances endothelium-\u00addependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp Biol Med 232:814\u2013822","journal-title":"Exp Biol Med"},{"key":"3_CR231","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.4161\/cc.7.14.6267","volume":"7","author":"M Potente","year":"2008","unstructured":"Potente M, Dimmeler S (2008) Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 7:2117\u20132122","journal-title":"Cell Cycle"},{"key":"3_CR232","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diabetes.55.01.06.db05-0926","volume":"55","author":"FM Matschinsky","year":"2006","unstructured":"Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, Taub R, Grimsby J (2006) The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55:1\u201312","journal-title":"Diabetes"},{"key":"3_CR233","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1042\/BST0330371","volume":"33","author":"B Leighton","year":"2005","unstructured":"Leighton B, Atkinson A, Coghlan MP (2005) Small molecule glucokinase activators as novel anti-diabetic agents. Biochem Soc Trans 33:371\u2013374","journal-title":"Biochem Soc Trans"},{"key":"3_CR234","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2850","volume":"8","author":"FM Matschinsky","year":"2009","unstructured":"Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8:399\u2013416","journal-title":"Nat Rev Drug Discov"},{"key":"3_CR235","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1126\/science.1084073","volume":"301","author":"J Grimsby","year":"2003","unstructured":"Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370\u2013373","journal-title":"Science"},{"key":"3_CR236","unstructured":"Drug candidates in development by phase. DiabesityDigest.com. http:\/\/diabesitydigest.com\/development.php?order=devel. Accessed 10 Jan 2013"},{"key":"3_CR237","doi-asserted-by":"crossref","first-page":"E463","DOI":"10.1152\/ajpendo.00163.2003","volume":"287","author":"C Broca","year":"2004","unstructured":"Broca C, Breil V, Cruciani-Guglielmacci C, Manteghetti M, Rouault C, Derouet M, Rizkalla S, Pau B, Petit P, Ribes G, Ktorza A, Gross R, Reach G, Taouis M (2004) Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat. Am J Physiol Endocrinol Metab 287:E463\u2013E471","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3_CR238","unstructured":"Boyd SA (2008) Arry-588 and Arry-403: novel glucokinase activators with potent glucose-\u00adlowering activity in animals of type 2 diabetes mellitus. SMI Metabolic Diseases Conference http:\/\/www.arraybiopharma.com\/_documents\/Publication\/PubAttachment297.pdf. Accessed 10 Jan 2013"},{"key":"3_CR239","unstructured":"Aicher T, Anderson D, Boyd S, Chicarelli M, Condroski K, DeWolf W Jr, Fell JB, Fischer J, Frank M, Galbraith S, Garrey R, Gunawardana I, Hinklin R, Hirsch J, Lee P, Neitzel N, Pratt S, Singh A, Thomas L, Turner T, Voegtli W, Wallace E, Williams L (2008) Discovery of ARRY-588, a novel glucokinase activator with potent glucose lowering activity in animal models of type 2 diabetes mellitus. www.arraybiopharma.com\/_documents\/Publication\/PubAttachment288.pdf. Accessed 10 Jan 2013"},{"key":"3_CR240","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2741\/3301","volume":"14","author":"DS Edgerton","year":"2009","unstructured":"Edgerton DS, Johnson KM, Cherrington AD (2009) Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Front Biosci 14:1169\u20131181","journal-title":"Front Biosci"},{"key":"3_CR241","first-page":"507","volume":"128","author":"MJH Kaal","year":"1993","unstructured":"Kaal MJH, Collet JT (1993) Inhibition of gluconeogenesis an option for the treatment of type 2 diabetes mellitus? Pharmaceut Week 128:507\u2013511","journal-title":"Pharmaceut Week"},{"key":"3_CR242","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ddmec.2008.01.001","volume":"4","author":"PD Poelje van","year":"2007","unstructured":"van Poelje PD, Dang Q, Erion MD (2007) Fructose-1,6-bisphosphatase as a therapeutic target for type 2 diabetes. Drug Discov Today 4:103\u2013109","journal-title":"Drug Discov Today"},{"key":"3_CR243","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1073\/pnas.0502983102","volume":"102","author":"MD Erion","year":"2005","unstructured":"Erion MD, van Poelje PD, Dang Q (2005) MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci USA 102:7970\u20137975","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR244","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2337\/diacare.28.2.427","volume":"28","author":"N Freemantle","year":"2005","unstructured":"Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FD, Martinez L, Ross S, Bolinder B, Stridde E (2005) Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 28:427\u2013428","journal-title":"Diabetes Care"},{"key":"3_CR245","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/193229680900300322","volume":"3","author":"E Arbit","year":"2009","unstructured":"Arbit E, Kidron M (2009) Oral insulin: the rationale for this approach and current developments. J Diabetes Sci Technol 3:562\u2013567","journal-title":"J Diabetes Sci Technol"},{"key":"3_CR246","first-page":"43","volume":"8","author":"A Amin","year":"2008","unstructured":"Amin A, Shah T, Patel J, Gajjar A (2008) Annual update on non-invasive insulin delivery \u00adtechnologies. Drug Deliv Technol 8:43\u201348","journal-title":"Drug Deliv Technol"},{"key":"3_CR247","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.metabol.2003.07.021","volume":"53","author":"S Clement","year":"2004","unstructured":"Clement S, Dandona P, Still JG, Kosutic G (2004) Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I\/II clinical trial. Metabolism 53:54\u201358","journal-title":"Metabolism"},{"key":"3_CR248","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.addr.2009.09.006","volume":"61","author":"S Maher","year":"2009","unstructured":"Maher S, Leonard TW, Jacobsen J, Brayden DJ (2009) Safety and efficacy of sodium caprate in promoting oral drug absorption: from in\u00a0vitro to the clinic. Adv Drug Deliv Rev 61:1427\u20131449","journal-title":"Adv Drug Deliv Rev"},{"key":"3_CR249","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nrd895","volume":"1","author":"TO Johnson","year":"2002","unstructured":"Johnson TO, Ermolieff J, Jirousek MR (2002) Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov 1:696\u2013709","journal-title":"Nat Rev Drug Discov"},{"key":"3_CR250","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.2174\/1381612043382954","volume":"10","author":"Z Pei","year":"2004","unstructured":"Pei Z, Liu G, Lubben TH, Szczepankiewicz BG (2004) Inhibition of protein tyrosine phosphatase 1B as a potential treatment of diabetes and obesity. Curr Pharm Des 10:3481\u20133504","journal-title":"Curr Pharm Des"},{"key":"3_CR251","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1385\/CBB:44:1:073","volume":"44","author":"MZ Mehdi","year":"2006","unstructured":"Mehdi MZ, Pandey SK, Th\u00e9berge JF, Srivastava AK (2006) Insulin signal mimicry as a mechanism for the insulin-like effects of vanadium. Cell Biochem Biophys 44:73\u201381","journal-title":"Cell Biochem Biophys"},{"key":"3_CR252","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1464-5491.2004.01381.x","volume":"22","author":"AK Srivastava","year":"2005","unstructured":"Srivastava AK, Mehdi MZ (2005) Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet Med 22:2\u201313","journal-title":"Diabet Med"},{"key":"3_CR253","first-page":"303","volume":"24","author":"G Vardatsikos","year":"2009","unstructured":"Vardatsikos G, Mehdi MZ, Srivastava AK (2009) Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes to its glucoregulatory responses. Int J Mol Med 24:303\u2013309","journal-title":"Int J Mol Med"},{"key":"3_CR254","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/dmrr.1116","volume":"26","author":"M Bertolaso","year":"2010","unstructured":"Bertolaso M, Olsson J, Picardi A, Rakela J (2010) Gene therapy and enhancement for diabetes (and other diseases): the multiplicity of considerations. Diabetes Metab Res Rev 26:520\u2013524","journal-title":"Diabetes Metab Res Rev"},{"key":"3_CR255","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1357-4310(98)01425-7","volume":"5","author":"F Levine","year":"1999","unstructured":"Levine F, Leibowitz G (1999) Towards gene therapy of diabetes mellitus. Mol Med Today 5:165\u2013171","journal-title":"Mol Med Today"},{"key":"3_CR256","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1073\/pnas.89.18.8822","volume":"89","author":"SP Smeekens","year":"1992","unstructured":"Smeekens SP, Montag AG, Thomas G, Albiges-Rizo C, Carroll R, Benig M, Phillips LA, Martin S, Ohagi S, Gardner P, Swift HH, Steiner DF (1992) Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. Proc Natl Acad Sci USA 89:8822\u20138826","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR257","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.addr.2009.03.015","volume":"61","author":"JC Won","year":"2009","unstructured":"Won JC, Rhee BD, Ko KS (2009) Glucose-responsive gene expression system for gene therapy. Adv Drug Deliv Rev 61:633\u2013640","journal-title":"Adv Drug Deliv Rev"},{"key":"3_CR258","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4161\/self.1.3.12643","volume":"1","author":"MS Wong","year":"2010","unstructured":"Wong MS, Hawthorne WJ, Manolios N (2010) Gene therapy in diabetes. Self Nonself 1:165\u2013175","journal-title":"Self Nonself"},{"key":"3_CR259","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/mt.2010.255","volume":"19","author":"J Han","year":"2011","unstructured":"Han J, McLane B, Kim EH, Yoon JW, Jun HS (2011) Remission of diabetes by insulin gene therapy using a hepatocyte-specific and glucose-responsive synthetic promoter. Mol Ther 19:470\u2013478","journal-title":"Mol Ther"},{"key":"3_CR260","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3109\/14653249.2011.571248","volume":"13","author":"C Limbert","year":"2011","unstructured":"Limbert C, P\u00e4th G, Ebert R, Rothhammer V, Kassem M, Jakob F, Seufert J (2011) PDX1- and NGN3-mediated in\u00a0vitro reprogramming of human bone marrow-derived mesenchymal stromal cells into pancreatic endocrine lineages. Cytotherapy 13:802\u2013813","journal-title":"Cytotherapy"},{"key":"3_CR261","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1387\/ijdb.092953hk","volume":"54","author":"H Kajiyama","year":"2009","unstructured":"Kajiyama H, Hamazaki TS, Tokuhara M, Masui S, Okabayashi K, Ohnuma K, Yabe S, Yasuda K, Ishiura S, Okochi H, Asashima M (2009) Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in\u00a0vivo and reduce hyperglycaemia in diabetic mice. Int J Dev Biol 54:699\u2013705","journal-title":"Int J Dev Biol"},{"key":"3_CR262","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nm867","volume":"9","author":"H Kojima","year":"2003","unstructured":"Kojima H, Fujimiya M, Matsumura K, Younan P, Imaeda H, Maeda M, Chan L (2003) NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med 9:596\u2013603","journal-title":"Nat Med"},{"key":"3_CR263","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1089\/cell.2010.0030","volume":"12","author":"S Gefen-Halevi","year":"2010","unstructured":"Gefen-Halevi S, Rachmut IH, Molakandov K, Berneman D, Mor E, Meivar-Levy I, Ferber S (2010) NKX6.1 promotes PDX-1-induced liver to pancreatic \u03b2-cells reprogramming. Cell Reprogram 12:655\u2013664","journal-title":"Cell Reprogram"},{"key":"3_CR264","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/bjo.62.6.351","volume":"62","author":"JG Cunha-Vaz","year":"1978","unstructured":"Cunha-Vaz JG (1978) Pathophysiology of diabetic retinopathy. Br J Ophthalmol 62:351\u2013355","journal-title":"Br J Ophthalmol"},{"key":"3_CR265","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/ni0901-810","volume":"2","author":"A Cooke","year":"2011","unstructured":"Cooke A, Phillips JM, Parish NM (2011) Tolerogenis strategies to halt or prevent type 1 diabetes. Nat Immunol 2:810\u2013815","journal-title":"Nat Immunol"},{"key":"3_CR266","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2337\/db09-0694","volume":"59","author":"SA Long","year":"2010","unstructured":"Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum C, Buckner JH (2010) Defects in IL-2R signaling contribute to \u00addiminished maintenance of FOXP3 expression in CD4(+)CD5(+) regulatory T-cells of type 1 diabetes subjects. Diabetes 59:407\u2013415","journal-title":"Diabetes"},{"key":"3_CR267","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","volume":"27","author":"CL Bennett","year":"2001","unstructured":"Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations in FOXP3. Nat Genet 27:20\u201321","journal-title":"Nat Genet"},{"key":"3_CR268","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/eji.201040890","volume":"41","author":"KS Goudy","year":"2011","unstructured":"Goudy KS, Johnson MC, Garland A, Li C, Samulski RJ, Wang B, Tisch R (2011) Reduced IL-2 expression in NOD mice leads to a temporal increase in CD62LIo FoxP3+ CD4+ T cells with limited suppressor activity. Eur J Immunol 41:1480\u20131490","journal-title":"Eur J Immunol"},{"key":"3_CR269","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/mt.2008.116","volume":"16","author":"KK Rehman","year":"2008","unstructured":"Rehman KK, Trucco M, Wang Z, Xiao X, Robbins PD (2008) AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice. Mol Ther 16:1409\u20131416","journal-title":"Mol Ther"},{"key":"3_CR270","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/gt.2011.25","volume":"18","author":"M Jean","year":"2011","unstructured":"Jean M, Alameh M, Buschmann MD, Merzouki A (2011) Effective and safe gene-based delivery of GLP-1 using chitosan\/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Gene Ther 18:807\u2013816","journal-title":"Gene Ther"},{"key":"3_CR271","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/gt.2009.143","volume":"17","author":"MJ Riedel","year":"2010","unstructured":"Riedel MJ, Gaddy DF, Asadi A, Robbins PD, Kieffer TJ (2010) DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes. Gene Ther 17:171\u2013180","journal-title":"Gene Ther"},{"key":"3_CR272","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.2337\/db09-0782","volume":"59","author":"SM Bindom","year":"2010","unstructured":"Bindom SM, Hans CP, Xia H, Boulares AH, Lazartigues E (2010) Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59:2540\u20132548","journal-title":"Diabetes"},{"key":"3_CR273","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2337\/diab.38.10.1203","volume":"38","author":"RL Engerman","year":"1989","unstructured":"Engerman RL (1989) Pathogenesis of diabetic retinopathy. Diabetes 38:1203\u20131206","journal-title":"Diabetes"},{"key":"3_CR274","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405\u2013412","journal-title":"BMJ"},{"key":"3_CR275","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.gt.3302653","volume":"13","author":"PA Campochiaro","year":"2006","unstructured":"Campochiaro PA (2006) Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 13:559\u2013562","journal-title":"Gene Ther"},{"key":"3_CR276","doi-asserted-by":"crossref","first-page":"18769","DOI":"10.1073\/pnas.0910561106","volume":"106","author":"K Sarkar","year":"2009","unstructured":"Sarkar K, Fox-Talbot K, Steenbergen C, Bosch-Marc\u00e9 M, Semenza GL (2009) Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci USA 106:18769\u201318774","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR277","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2337\/db09-0336","volume":"59","author":"SM Samuel","year":"2010","unstructured":"Samuel SM, Akita Y, Paul D, Thirunavukkarasu M, Zhan L, Sudhakaran PR, Li C, Maulik N (2010) Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats. Diabetes 59:51\u201360","journal-title":"Diabetes"},{"key":"3_CR278","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.2337\/diabetes.53.12.3226","volume":"53","author":"SB Catrina","year":"2004","unstructured":"Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L (2004) Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes 53:3226\u20133232","journal-title":"Diabetes"},{"key":"3_CR279","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1524-475X.2007.00278.x","volume":"15","author":"KA Mace","year":"2007","unstructured":"Mace KA, Yu DH, Paydar KZ, Boudreau N, Young DM (2007) Sustained expression of Hif-\u00ad1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair. Wound Repair Regen 15:636\u2013645","journal-title":"Wound Repair Regen"},{"key":"3_CR280","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/jcp.21503","volume":"217","author":"L Liu","year":"2008","unstructured":"Liu L, Marti GP, Wei X, Zhang X, Zhang H, Liu YV, Nastai M, Semenza GL, Harmon JW (2008) Age-dependent impairment of HIF-1alpha expression in diabetic mice: correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. J Cell Physiol 217:319\u2013327","journal-title":"J Cell Physiol"},{"key":"3_CR281","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1007\/s00125-011-2191-8","volume":"54","author":"CF Bento","year":"2011","unstructured":"Bento CF, Pereira P (2011) Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. Diabetologia 54:1946\u20131956","journal-title":"Diabetologia"},{"key":"3_CR282","doi-asserted-by":"crossref","first-page":"10930","DOI":"10.1074\/jbc.M707451200","volume":"283","author":"DJ Ceradini","year":"2008","unstructured":"Ceradini DJ, Yao D, Grogan RH, Callaghan MJ, Edelstein D, Brownlee M, Gurtner GC (2008) Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 283:10930\u201310938","journal-title":"J Biol Chem"},{"key":"3_CR283","doi-asserted-by":"crossref","first-page":"e15062","DOI":"10.1371\/journal.pone.0015062","volume":"5","author":"CF Bento","year":"2010","unstructured":"Bento CF, Fernandes R, Ramalho J, Marques C, Shang F, Taylor A, Pereira P (2010) The chaperone-dependent ubiquitin ligase CHIP targets HIF-1\u03b1 for degradation in the presence of methylglyoxal. PLoS One 5:e15062","journal-title":"PLoS One"},{"key":"3_CR284","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1189\/0507306","volume":"82","author":"J Wang","year":"2007","unstructured":"Wang J, Jiao H, Stewart TL, Lyons MV, Shankowsky HA, Scott PG, Tredget EE (2007) Accelerated wound healing in leukocyte-specific, protein 1-deficient mouse is associated with increased infiltration of leukocytes and fibrocytes. J Leukoc Biol 82:1554\u20131563","journal-title":"J Leukoc Biol"},{"key":"3_CR285","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1038\/jid.2009.26","volume":"129","author":"H Brem","year":"2009","unstructured":"Brem H, Kodra A, Golinko MS, Entero H, Stojadinovic O, Wang VM, Sheahan CM, Weinberg AD, Woo SL, Ehrlich HP, Tomic-Canic M (2009) Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. J Invest Dermatol 129:2275\u20132287","journal-title":"J Invest Dermatol"},{"key":"3_CR286","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.gt.3302907","volume":"14","author":"GJ Prud\u2019homme","year":"2007","unstructured":"Prud\u2019homme GJ, Draghia-Akli R, Wang Q (2007) Plasmid-based gene therapy of diabetes mellitus. Gene Ther 14:553\u2013564","journal-title":"Gene Ther"},{"key":"3_CR287","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2337\/diabetes.51.6.1729","volume":"51","author":"MG Dube","year":"2002","unstructured":"Dube MG, Beretta E, Dhillon H, Ueno N, Kalra PS, Kalra SP (2002) Central leptin gene therapy blocks high-fat diet-induced weight gain, hyperleptinemia, and hyperinsulinemia: increase in serum ghrelin levels. Diabetes 51:1729\u20131736","journal-title":"Diabetes"},{"key":"3_CR288","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/156652306776359504","volume":"6","author":"GJ Prud\u2019homme","year":"2006","unstructured":"Prud\u2019homme GJ, Glinka Y, Khan AS, Draghia-Akli R (2006) Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 6:243\u2013273","journal-title":"Curr Gene Ther"},{"key":"3_CR289","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/gt.2010.164","volume":"18","author":"SP Kalra","year":"2011","unstructured":"Kalra SP (2011) Pivotal role of leptin-hypothalamus signaling in the aetiology of diabetes uncovered by gene therapy: a new therapeutic intervention? Gene Ther 18:319\u2013325","journal-title":"Gene Ther"},{"key":"3_CR290","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.peptides.2009.07.021","volume":"30","author":"SP Kalra","year":"2009","unstructured":"Kalra SP (2009) Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation. Peptides 30:1957\u20131963","journal-title":"Peptides"},{"key":"3_CR291","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hep.24140","volume":"53","author":"JM Orellana-Gavald\u00e0","year":"2011","unstructured":"Orellana-Gavald\u00e0 JM, Herrero L, Malandrino MI, Pa\u00f1eda A, Sol Rodr\u00edguez-Pe\u00f1a M, Petry H, Asins G, Van Deventer S, Hegardt FG, Serra D (2011) Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation. Hepatology 53:821\u2013832","journal-title":"Hepatology"},{"key":"3_CR292","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2004","unstructured":"Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047\u20131053","journal-title":"Diabetes Care"},{"key":"3_CR293","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00125-003-1263-9","volume":"47","author":"A Gastaldelli","year":"2004","unstructured":"Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47:31\u201339","journal-title":"Diabetologia"},{"key":"3_CR294","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cbpa.2009.04.622","volume":"13","author":"TE Hughes","year":"2009","unstructured":"Hughes TE (2009) Emerging therapies for metabolic diseases\u00a0\u2013\u00a0the focus is on diabetes and obesity. Curr Opin Chem Biol 13:332\u2013337","journal-title":"Curr Opin Chem Biol"}],"container-title":["Advances in Predictive, Preventive and Personalised Medicine","New Strategies to Advance Pre\/Diabetes Care: Integrative Approach by PPPM"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-94-007-5971-8_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:21:02Z","timestamp":1745972462000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-94-007-5971-8_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"ISBN":["9789400759701","9789400759718"],"references-count":295,"URL":"https:\/\/doi.org\/10.1007\/978-94-007-5971-8_3","relation":{},"ISSN":["2211-3495","2211-3509"],"issn-type":[{"value":"2211-3495","type":"print"},{"value":"2211-3509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]},"assertion":[{"value":"28 January 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}